JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265145

Human BUB1 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

BUB1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Human BUB1 knockout HeLa cell line (AB265145)
  • WB

Lab

Western blot - Human BUB1 knockout HeLa cell line (AB265145)

Lanes 1- 2 : Merged signal (red and green). Green - ab195268 observed at 125 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.

ab195268 was shown to react with Bub1 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab265145 (knockout cell lysate ab257373) was used. Wild-type HeLa and BUB1 knockout HeLa cell lysates were subjected to SDS-PAGE. ab195268 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4° at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Bub1 antibody [EPR18947] (<a href='/en-us/products/primary-antibodies/bub1-antibody-epr18947-ab195268'>ab195268</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

BUB1 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human BUB1 knockout HeLa cell line (ab265145)

Predicted band size: 122 kDa

Observed band size: 125 kDa

false

Sanger Sequencing - Human BUB1 knockout HeLa cell line (AB265145)
  • Sanger seq

Unknown

Sanger Sequencing - Human BUB1 knockout HeLa cell line (AB265145)

Homozygous : 1 bp insertion in exon 4.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4

Antibiotic resistance

Puromycin 1µg/mL

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265145-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265145-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265145 Human BUB1 knockout HeLa cell line", "number":"AB265145-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265145-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265145 Human BUB1 knockout HeLa cell line", "number":"AB265145-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
BUB1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Bub1 protein often referred to as 'Bub1' plays a mechanical role in cell cycle regulation especially during mitosis. It is known by other names such as BUB1 mitotic checkpoint serine/threonine kinase. Bub1 has a molecular mass of approximately 120 kDa. This protein is expressed in various tissues with higher levels in rapidly dividing cells. The location of its action is mainly the nucleus where it associates with kinetochores during cell division functioning in the spindle assembly checkpoint.
Biological function summary

Bub1 protein acts as a serine/threonine-protein kinase that is essential for proper chromosome segregation. It forms part of the spindle checkpoint complex along with other proteins such as BubR1 and Mad2. This complex ensures that chromosomes are correctly attached to the spindle microtubules before anaphase begins. Bub1's kinase activity contributes to the prevention of premature anaphase onset thereby helping maintain genomic stability.

Pathways

Bub1 is significantly involved in the mitotic checkpoint pathway and the cell cycle control pathway. Within these pathways Bub1 interacts closely with proteins like CDC20 and APC/C which are integral parts of the anaphase-promoting complex. Bub1 modifies the activity of these proteins to delay anaphase onset until all chromosomes are properly aligned ensuring the fidelity of cell division.

Bub1 protein shows a connection to various cancer types notably breast cancer and colorectal cancer. Defects or overexpression in Bub1 can disrupt the spindle assembly checkpoint leading to chromosome missegregation and aneuploidy hallmarks of cancerous cells. Bub1 is also linked to other spindle checkpoint proteins such as Mad1 and Bub3. Malfunction in any of these proteins including Bub1 can contribute to tumorigenesis due to impaired cell cycle control.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com